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Elevated microsatellite alterations at selected tetranucleotides (EMAST), a variation of microsatellite instability (MSI), has been
reported in a variety of malignancies (e.g., neoplasias of the lung, head and neck, colorectal region, skin, urinary tract and
reproductive organs). EMAST is more prominent at organ sites with potential external exposure to carcinogens (e.g., head, neck,
lung, urinary bladder and colon), although the specific molecular mechanisms leading to EMAST remain elusive. Because it is
often associated with advanced stages of malignancy, EMAST may be a consequence of rapid cell proliferation and increased
mutagenesis. Moreover, defects in DNA mismatch repair enzyme complexes, TP53 mutation status and peritumoural inflammation
involving T cells have been described in EMAST tumours. At various tumour sites, EMAST and high-frequency MSI share no
clinicopathological features or molecular mechanisms, suggesting their existence as separate entities. Thus EMAST should be
explored, because its presence in human cells may reflect both increased risk and the potential for early detection. In particular,
the potential use of EMAST in prognosis and prediction may yield novel types of therapeutic intervention, particularly those
involving the immune system. This review will summarise the current information concerning EMAST in cancer to highlight the
knowledge gaps that require further research.
Microsatellites are repeating units of one to six base pairs, which
are ubiquitous, abundant and repeated several times in eukaryotic
genomes. These repeats are prone to errors during DNA
replication, and the failure to correct such errors results in
microsatellite instability (MSI). Since its initial description as a
form of genetic instability in colorectal cancer (CRC), MSI has
been linked to a number of phenotypic characteristics and
clinicopathological features of tumours (Sinicrope and Sargent,
2012). The prognostic and predictive relevance of MSI in CRC has
been well documented (Sinicrope and Sargent, 2012). In CRC, MSI
is the hallmark of forms of hereditary non-polyposis CRC
(HNPCC; or Lynch syndrome) caused by germline mutations in
mismatch repair (MMR) genes. MSI is also detected in 15% of
sporadic CRC cases, usually as a consequence of epigenetically
silenced MMRs (Sinicrope and Sargent, 2012). Furthermore, the
presence of MSI has been demonstrated in other cancers, including
endometrial, ovarian and urinary tract cancers. Currently, MSI
appears to be a genetic aberration found in a wide range of human
solid tumours that is best defined in the context of colorectal
neoplasia; at tumour sites other than CRC, the clinical relevance
and frequency of MSI are variable (Catto et al, 2003; Pal et al, 2008;
Diaz-Padilla et al, 2013). In the clinical setting, such as when
screening for CRC, HNPCC or sporadic MSI, MSI is usually
classified as mononucleotide and dinucleotide repeats (Umar et al,
2004). Recently, a number of reports have also documented
instability at specific tetranucleotide repeats, a phenomenon
termed elevated microsatellite alterations at selected tetranucleo-
tide repeats (EMAST). As an emerging specific form of genetic
alteration, EMAST remains poorly described. However, EMAST
may hold clues for deeper insights into the roles of MSI in cancer
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biology, thus facilitating improved preventive, therapeutic and
prognostic/predictive strategies in human cancer. This review aims
to concisely present the current knowledge concerning EMAST in
human solid cancers; we briefly present the proposed molecular
mechanisms and describe the potential clinical implications for
human cancer.
MICROSATELLITES, REPEAT SIZE AND INSTABILITY
During DNA replication, microsatellites are prone to erroneous
duplication, which involves the addition or deletion of one or
several repeated units, and the failure of DNA proofreading
mechanisms to correct such errors results in instability at
microsatellites. Microsatellite alterations, such as the insertion/
deletion of a repeat, can produce deleterious effects via the
induction of strand slippage and frameshift mutations when a
protein-coding region is affected (Saeterdal et al, 2001; Kim et al,
2013). The results of such effects range from changes in the
physical and chemical properties of the translated proteins to
interference with transcription at promoter sites or the translation
of truncated and dysfunctional proteins.
Generally, repetitive elements can occur in a variety of patterns
and distributions (i.e., tandem, dispersed and paralogues). These
elements constitute as much as 50% of the genome, and
approximately one-fourth of empirically defined human promoters
are surrounded by or contain clustered repetitive elements.
However, the genomic distribution of microsatellites is rather
random; mononucleotides, dinucleotides and tetranucleotides are
primarily found in intronic and intergenic noncoding regions,
whereas other microsatellites (trinucleotides and hexanucleotides)
are located more abundantly within sequences involved in gene
transcription (Subramanian et al, 2003).
Previous attempts at defining MSI have not produced
straightforward results. Following the first MSI international
workshop at the National Cancer Institute (NCI) at Bethesda in
1998, the 2004 revised NCI/Bethesda microsatellite screening panel
(Umar et al, 2004), which is based on five mononucleotide and
dinucleotide microsatellites, defined ‘classical’ MSI as high-
frequency (MSI-H; X2 out of 5 markers are unstable or X40%),
low-frequency (MSI-L; 1 out of 5 markers is unstable orX20% and
o40%) or microsatellite-stable (MSS; no unstable markers
detected). In CRC, there is a consensus on the definitions of MSI
for clinical use (Umar et al, 2004), although defining the different
degrees of instability remains a matter of controversy. Based on the
Bethesda panel, MSS, MSI-L and MSI-H tumours contain different
numbers of altered microsatellites, suggesting that these forms of
MSI represent separate phenomena, at least at the molecular level.
However, MSS tumours and MSI-L unstable tumours are typically
grouped together, because both present similar clinical forms and
gross abnormalities. Notably, MSI-L is generally detected only
when dinucleotide markers are used, and some authors have
disputed the existence of MSI-L completely (Kim et al, 2013). MSI
is found with the highest frequency in mononucleotide repeats,
which are also the most frequently occurring nucleotide repeats
throughout the genome. Notably, tetranucleotide repeats occur at a
much lower frequency than mononucleotide repeats, and it is not
known whether forms of MSI involving nucleotide repeats of
different sizes share common underlying mechanisms. However,
the most clinically relevant microsatellites studied in cancer are
composed of mononucleotide (e.g., Gn), dinucleotide (e.g., CAn) or
tetranucleotide (e.g., AAAGn) repeats. Variations in the number of
repeats in microsatellite sequences among the population are
defined as microsatellite polymorphisms, as opposed to MSI, which
refers to such alterations within multiple cells of the same
individual (e.g., when comparing tumour and normal tissues).
Instability at tetranucleotides represents a variation of MSI that
was not addressed by the Bethesda definitions (Umar et al, 2004),
which are based on mononucleotide and dinucleotide markers.
However, in most EMAST-associated cancers, instability occurs at
loci containing AAAGn or ATAGn repeats.
PREVALENCE AND RELEVANCE OF EMAST IN HUMAN
CANCERS
EMAST has been reported in several cancers of solid organs
(Figure 1), including the colorectum (Haugen et al, 2008; Devaraj
et al, 2010; Lee et al, 2010; Lee et al, 2012), lungs (Ahrendt et al,
2000; Xu et al, 2001; Arai et al, 2013), ovaries (Singer et al, 2004),
bladder (Xu et al, 2001; Danaee et al, 2002; Catto et al, 2003;
Burger et al, 2006a), prostate (Perinchery et al, 2000; Burger et al,
2006b; Azzouzi et al, 2007), kidney (Xu et al, 2001; Catto et al,
2003), head and neck (Xu et al, 2001; Temam et al, 2004), non-
melanoma skin (Danaee et al, 2002) and uterus (Choi et al, 2008).
The estimated prevalence of EMAST according to previously
reported studies is presented in Table 1. In fact, the reported
prevalence and relationship between EMAST and clinicopatholo-
gical features and molecular mechanisms vary considerably across
tumour sites (Figure 1).
CRCs. Presumably because of the great impact that MSI has had
on the understanding of human cancer biology, the vast majority
of EMAST-related reports in the scientific literature concern CRC.
EMAST is found most frequently (460%) in advanced-stage
CRC with poor tumour differentiation (Lee et al, 2010). The
documented presence of EMAST in adenomas has been incon-
sistent, with reports ranging from 0% (Lee et al, 2012) to 33% (Lee
et al, 2010). The overall frequency of EMAST in CRC is much
higher (up to 60%) than the frequency of classical MSI-H (usually
15–20%) (Yamada et al, 2010), and EMAST occurs at high rates in
rectal cancers (Devaraj et al, 2010). EMAST is associated with the
MSI-L classification and demonstrates a worse prognosis with a
shorter time to recurrence and development of distant metastasis
in stage II and III CRC (Garcia et al, 2012). This worse prognosis is
observed regardless of the association of EMAST with greater
infiltration of CD8þ T cells in both the tumour and surrounding
stroma (Devaraj et al, 2010; Lee et al, 2012), a feature usually
associated with better prognosis in CRC. Thus the dual role of
inflammation in this setting warrants further investigation.
Respiratory tract cancers. The reported frequency of EMAST in
lung cancers ranges from 32% to 64.5% (Ahrendt et al, 2000;
Xu et al, 2001; Woenckhaus et al, 2003; Arai et al, 2013). However,
there appears to be a distinction between EMAST and MSI-H, and
mutations in TP53 are common in EMAST cancers (Ahrendt et al,
2000; Xu et al, 2001; Woenckhaus et al, 2003). EMAST was found
to be most prevalent in cases of the squamous subtype and early
stage disease (Xu et al, 2001; Woenckhaus et al, 2003; Arai et al,
2013), although it was associated with higher rates of lymph node
metastasis in another study (Woenckhaus et al, 2003). Addition-
ally, one study found a higher incidence of previous cancer history
in patients with EMAST (Arai et al, 2013), potentially suggesting a
‘field defect’ or cancer susceptibility related to EMAST.
Kidney and urinary tract cancers. The frequency of EMAST in
cancers of urogenital organs is markedly lower compared with that
in other solid tumours and is higher in the lower urinary tract
(urinary bladder) than the upper urinary tract (kidneys, ureters
and renal pelvis) (see Table 1, Figure 1).
In bladder cancer, EMAST-positive tumours (approximately
one-third of bladder tumours) have been associated with TP53
mutations and non-invasive lesions (Danaee et al, 2002). However,
a much lower EMAST frequency (5.3%) was demonstrated
in a large, non-selected cohort of urothelial bladder cancers, and
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EMAST was not found to be associated with TP53 status (Burger
et al, 2006a). In the urinary tract, EMAST appears to be unrelated
to classical MSI and occurs less frequently in the renal pelvis (Catto
et al, 2003). No firm associations between EMAST and
clinicopathological features or clinical outcomes have been
reported (Danaee et al, 2002; Catto et al, 2003; Burger et al,
2006a). The reported EMAST frequency in renal cell carcinomas is
very low, ranging fromo1% (Stoehr et al, 2012) to 12% (Xu et al,
2001). Based on the limited available evidence, it appears that the
prevalence of EMAST decreases from the upper to the lower
urinary tract, with no solid clinical relationships or molecular
mechanisms having been established in this area.
Reproductive organs. In cancers of the reproductive organs,
EMAST occurs slightly more often in malignancies of the female
reproductive organs, such as the ovaries (13%, Singer et al, 2004)
Table 1. Prevalence of EMAST among human solid malignancies
Site Author, year Cohort size (n) Definitions Prevalence (%)
Bladder Xu et al, 2001 38 X1/12 markers unstable 21%
Burger et al, 2006a, b 117 X1/10 markers unstable 9%
Catto et al, 2003 89 X1/8 markers unstable 45%
Danaee et al, 2002 57 X1/7 markers unstable 44%
Colorectal Lee et al, 2010 108 X2/5 markers 50%
Lee et al, 2012 108 X2/5 markers 50%
Devaraj et al, 2010 147 (only rectal) X2/5 markers 33%
Haugen et al, 2008 117 X1/7 markers unstable 60%
NSCLC Xu et al, 2001 47 X1/12 markers unstable 51%
Arai et al, 2013 65 X1/10 markers unstable 65%
Ahrendt et al, 2000 88 X1/13 markers unstable 35%
Prostate Burger et al, 2006a, b 81 X1/10 markers unstable 5%
Azzouzi et al, 2007 50 X2/4 markers 4%
Perinchery et al, 2000 40 X1/4 markers 25%
Renal Xu et al, 2001 25 X1/12 markers unstable 12%
Catto et al, 2003 71 (upper urinary tract) X1/8 markers unstable 23%
Head and neck Xu et al, 2001 18 X1/12 markers unstable 56%
Temam et al, 2004 54 X1/5 markers 48%
Non-melanoma skin Danaee et al, 2002 61 X1/7 markers unstable 75%
Ovarian Singer et al, 2004 53 X1/6 markers unstable 19%
Endometrial Choi et al, 2008 39 X1/6 markers unstable and no instability in mononucleotides and
dinucleotides
39%
Abbreviation: NSCLC¼ non-small cell lung cancer.
Head and neck cancer
Skin cancer
Renal cancer
Upper urothelial tract
cancer
Ovarian cancer
Endometrial cancer
Lung cancer, non-small
cell (NSCLC)
Colorectal cancer
Bladder cancer
Prostate cancer
Prevalence 48–56%
Non-melanoma
Prevalence 75%
Related to LOH in p53 and PTCH
Prevalence <1–12%
Prevalence 23%
Associated with MSI-H
Prevalence 0–19%
Most often in serous
carcinoma (9%)
Prevalence 39%
Loss of MLH1, MSH2 in 33%
Loss of p53 in about 50%
Prevalence 35–65%
Often mutated p53, squamous
differentiation, stage I–II, pN+
No association with ‘classical’ MSI
Prevalence 33–60%
Reduced survival; T-cell infiltration,
often advanced tumour features
Downregulated MSH3
Prevalence 9–45%
No association with p53
No association with stage, grade, or
outcome
No association with classical MSI
Prevalence 4–25%
Not in early disease
Figure 1. Prevalence and main observed features of EMAST in human solid cancers.
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and uterus (38.5%, Choi et al, 2008), compared with the male
reproductive organs, although the overall available literature
remains limited.
Classical MSI is noted in approximately 12% of ovarian
cancers (Pal et al, 2008) and is most frequently associated with the
non-serous histological type. In contrast, EMAST appears predo-
minantly in the serous subtype of ovarian cancers; no EMAST has
been found in non-serous carcinomas (Singer et al, 2004).
Approximately 15% of endometrial cancers exhibit MSI-H, but
there are conflicting reports of the relation to clinical outcome (Diaz-
Padilla et al, 2013). EMAST has been reported at a higher frequency
(39%) than classical MSI, but these two markers showed no correlation
in type I endometrial carcinomas. Furthermore, most (70%) EMAST-
positive tumours exhibited normal expression of both MSH2 and
MLH1 in immunohistochemical analyses (Choi et al, 2008).
In prostate cancer, MSI is generally prevalent at dinucleotide
tandem repeats and is less common in trinucleotide and
tetranucleotide repeats (Perinchery et al, 2000). According to most
reports, the frequency of EMAST in prostate cancer iso5%
(Terrell et al, 1995; Burger et al, 2006b; Azzouzi et al, 2007).
In prostate cancer, EMAST is related neither to MSI nor to defects
in MMR proteins, TP53 mutational status or any histopathological
features (Burger et al, 2006b).
Other malignancies. Instabilities in tetranucleotide repeats have
been reported in both the MSI-H and MSI-L types of gastric
tumours, although EMAST has not been specifically investigated
in this setting (Kim et al, 2001). In a small study of 22 pheo-
chromocytomas (Kupka et al, 2008), 2 patients demonstrated MSI
in 1 and 2 of three tetranucleotide repeats (D2S443, D16S752 and
D21S1436) investigated; both cancers were defined as MSI-L by the
Bethesda panel. None of the endocrine tumours in that study
exhibited instability in the tetranucleotide markers used, although
13% were classified as MSI-H (Kupka et al, 2008).
EMAST was also analysed in one study of non-melanoma skin
cancer, where it was found at a high incidence (75%) and was
associated with TP53 or PTCH (patched gene) loss of hetero-
zygosity (Danaee et al, 2002). PTCH acts as receptor in the sonic
hedgehog signalling pathway, and loss-of-function mutations in
PTCH contribute to skin cancer development. The PTCH
gene harbours mutational hot-spot residues and regions,
including a slippage-sensitive sequence at the N-terminus
(Lindstrom et al, 2006).
EMAST frequencies in head and neck cancers have been reported
to range from 48% to 56% (Xu et al, 2001; Temam et al, 2004). Of
clinical relevance was one report showing that patients with
histologically proven (¼R0) radical and curative surgery, but who
displayed EMAST at the resection margins, had a higher risk of
tumour recurrence (Temam et al, 2004). ‘Molecular-positive’ resection
margins may thus be proposed as grounds for more aggressive
treatment or surveillance if validated as a broadened concept.
More recently, the length of an AAAG tetranucleotide repeat
tract and polymorphisms in a tetranucleotide repeat, both located
within the KCNQ1OT1 gene, have been shown to correlate with an
increased risk of breast cancer (Karimi et al, 2013) and
hepatocellular carcinoma (Wan et al, 2013), respectively.
CONCLUSIONS
The molecular mechanisms of EMAST have yet to be clearly
unravelled. EMAST induction and its contribution to carcinogen-
esis may stem from both exposure to external mutagens and
malfunctioning intrinsic cellular mechanisms. Experiments have
suggested that long microsatellites with higher numbers of repeats may
be prone to replication errors at higher frequencies compared with the
shorter ones. However, the consequences of EMAST development in
carcinogenesis require further investigation. The results from human
solid cancers have led to proposed mechanisms involving DNA repair
by TP53 and MSH3 and have suggested the immunological
involvement of T cells, at least in CRC, although precise mechanistic
understanding clearly requires further investigation.
The potential role of EMAST in early detection, prognostication
and prediction has been poorly investigated. However, some
findings have revealed the potential future use of this marker in
cancer. Variations of specific lengths in certain polymorphic
tetranucleotide repeats are associated with an increased cancer
risk, as recently reported for breast cancer and hepatocellular
carcinomas (Karimi et al, 2013; Wan et al, 2013). The high
prevalence of EMAST in the early stages of some cancers,
particularly those of the upper respiratory organs and lower
urinary tract, may suggest EMAST as a potentially exploitable
marker for preventive/early detection screening. In fact, in biopsies
from endoscopically normal colons, MSI in mononucleotide and
dinucleotide markers has been observed earlier than neoplastic
changes (Tug et al, 2012). Although markers suggestive of EMAST
have yet to be explored in the same manner, they EMAST markers
may be found more abundantly, because EMAST occurs at higher
frequencies. EMAST may also be generally related to environ-
mental carcinogen exposure and may therefore serve as a marker
of exposure or risk in certain cancers.
EMAST in the tissues of apparently tumour-free marginal sites
of surgical resections has been correlated with disease recurrence
(Temam et al, 2004). Therefore, EMAST in the tissues
of histomorphologically normal (R0 resected) surgical cancer
specimens could be used as a prognostic predictor of disease
recurrence in head and neck cancers. Optimal marker selection
may also lead to the feasibility of urine analysis for the early
detection or postsurgical surveillance of patients with bladder
cancer (van Tilborg et al, 2012).
Finally, the prognostic value of different forms of MSI in CRC
warrants further research (Garcia et al, 2012). The 5-year
recurrence-free survival trends for EMAST-positive and MSI-L
tumours are worse compared with those of MSI-H tumours,
suggesting differences in tumour biology that are currently not
fully appreciated and that may have consequences for the use of the
other available predictive and prognostic markers.
Taken together, these data suggest that EMAST should be
further investigated for its potential use in screening and/or as a
prognostic and predictive biomarker. In the fields of clinical and
translational oncology, important steps need to be taken to
improve the understanding of the role of EMAST in cancer. In our
view, one unresolved issue remains regarding whether EMAST
represents an ‘innocent bystander’ in cancer or an ‘active partner’
in carcinogenesis. Based on the emerging findings and cumulative
reports discussed above, EMAST may have diverse roles in
carcinogenesis and tumour biology at different tumour sites.
Nevertheless, common underlying principles may be crucial for
understanding cancer behaviour and may yield new tools for
prevention, early detection or personalised treatment.
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